TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03608241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: 200 mg by mouth (PO) Once daily (QD) for 11 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: 200 mg by mouth (PO) Once daily (QD) for 11 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (EE) and levonogestrel (LN)
Description: Single dose of Oral tablet containing 30 ug EE and 150 ug of LN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (EE) and levonogestrel (LN)
Description: Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
Study: NCT02371577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events Duration of lenalidomide on the clinical trial is for up to 6 cycles, each of 28 day duration.
Study: NCT02482298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Two arms: 1) 10 mg ticagrelor + 45 mg ticagrelor placebo or 2) 45 mg ticagrelor + 10 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening, at least 12 hours apart) from randomization until the end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Two arms: 1) 10 mg ticagrelor + 45 mg ticagrelor placebo or 2) 45 mg ticagrelor + 10 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening, at least 12 hours apart) from randomization until the end of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg ticagrelor placebo + 45 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening at least 12 hours apart) from randomization until the end of treatment
Study: NCT02681419

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needle fenestration
Description: This technique creates fenestrations along a nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture wick
Description: This technique places a single 10-vicryl suture wick through the nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
Study: NCT05130905

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RiteStart Supplement
Description: RiteStart is a comprehensive multivitamin, multimineral, all-in-one daily supplement. Besides having comprehensive and balanced amounts of essential vitamins and minerals that the human body needs, RS includes many other health-promoting ingredients. For example, RS contains potent antioxidants, including vitamins A, C, and E, oligomeric proanthocyanidins from pinebark and grapeseed extracts, lutein, CoQ10, alpha-lipoic acid, and green tea. It is also a source of essential fatty acids from fish and plant oils. RS contains transfer factor (bovine colostrum and egg yolk extracts) that support immunity \[6, 7, 8\]. RS also includes a blend of maitake mushrooms, shiitake mushrooms, cordyceps, inositol hexaphosphate, olive leaf extract, and other ingredients that aim to further support immune function and overall health.
Study: NCT04401800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Capsules administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Capsules administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg intravenous (IV) infusion administered on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg intravenous (IV) infusion administered on Day 1 of each cycle
Study: NCT02668705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embodied Conversational Agent
Description: A computer generated character that can administer informed consent to a potential research subject.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embodied Conversational Agent
Description: A computer generated character that can administer informed consent to a potential research subject.
Study: NCT04408391

Intervention type: OTHER
Intervention: Brain MRI scan
Description: Resting state, functional, structural and morphometric MRI; diffusion tensor imaging on a 3-Tesla MRI scanner

Intervention type: OTHER
Intervention: Brain MRI scan
Description: Resting state, functional, structural and morphometric MRI; diffusion tensor imaging on a 3-Tesla MRI scanner
Study: NCT01643642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment/farmacotherapy intervention
Description: Brief cognitive behavioral intervention/farmacotherapy; intake, treatment and ROM

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment As Usual
Description: Other: Treatment As Usual
Study: NCT01270932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and Dexamethasone
Description: Lenalidomide:Daily for 21 days of a 28 day cycle Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4.
Study: NCT00880269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat/LBH589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat/LBH589
Study: NCT00352469

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Seroquel XR
Description: Day 1 and 2 Seroquel XR 50 mg; Day 3-4 Seroquel XR 150mg;Day 5-42 Seroquel XR 300-400mg
Study: NCT03337802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mediterranean diet
Description: The Mediterranean diet (MD) is highly regarded as a healthy balanced diet. It is distinguished by a beneficial fatty acid profile that is rich in both monounsaturated and polyunsaturated fatty acids, high levels of polyphenols and other antioxidants, high intake of fiber and other low glycemic carbohydrates, and relatively greater vegetable than animal protein intake. Specifically, olive oil, assorted fruits, vegetables, cereals, legumes, and nuts; moderate consumption of fish, poultry, and red wine; and a lower intake of dairy products, red meat, processed meat and sweets characterize the traditional MD.
Study: NCT03818763

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII
Description: Reduced intensity conditioning with melphalan and fludarabine, followed by a single infusion of autologous CD34+PBSC, transduced with a lentiviral vector (-889ITGA2B-BDDFVIII-WPTS(MUT6)(VSVg)) also known as (Pleightlet(MUT6)) encoding the B domain deleted from of human coagulation factor VIII (BDDFVIII) in up to five hemophilia A patients with a history of FVIII inhibitors (≥0.6BU).~The infusion volume of transduced cells will not exceed 20 ml/kg body weight.
Study: NCT03050450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
Description: Drug: Lenalidomide 25 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
Description: Drug: Lenalidomide 50 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
Description: Drug: Lenalidomide 100 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
Description: Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)
Description: Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 230 mg/m2 days 1-7 and 15-21 of a 28 day cycle
Study: NCT03592771

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: THRIVE App
Description: Participants in the THRIVE App group receive a weekly text message to prompt them to log into the THRIVE app to answer questions about their AET adherence and related adverse symptoms. The app can be accessed through any web-enabled device or Internet browser. All participant-reported data will be automatically entered into the patient's electronic health record and easily available to the care team for review. Any concerning symptoms or changes will trigger an email alert to the patient's oncology team.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: THRIVE App
Description: Participants in the THRIVE App group receive a weekly text message to prompt them to log into the THRIVE app to answer questions about their AET adherence and related adverse symptoms. The app can be accessed through any web-enabled device or Internet browser. All participant-reported data will be automatically entered into the patient's electronic health record and easily available to the care team for review. Any concerning symptoms or changes will trigger an email alert to the patient's oncology team.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Feedback Messages
Description: Participants receive weekly tailored feedback messages and/or images based on their baseline survey responses and use of the app during the 6-month intervention phase. Some tailored feedback includes links to symptom-specific educational materials and coping strategies for participants who report low-severity symptoms. Message categories are tailored to participant's responses to the app and baseline survey.
Study: NCT00907322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Oral tablet; 20 mg Dimebon, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Oral tablet; 40 mg Dimebon, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Oral tablet; 60 mg Dimebon, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Oral tablet; placebo, single dose
Study: NCT04778891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Medication Management services
Description: Comprehensive Medication Management services (CMM services) is an evidence-based and patient-centred service which involves an assessment of patient's medications to determine that each medication is appropriate, effective for the medical condition being treated, safe for the patient in the presence of other medications and co-morbidities, and that the patient is able and willing to take the medications as intended. As all patient care providers need a structured, rational thought process for sound clinical decision retrieval, the Pharmacotherapy Workup was developed and adopted as a systematic problem-solving process. This process represents the cognitive work taking place in the mind of the practitioner, and is used to identify, resolve, and prevent drug therapy problems (DTP), establish therapy goals, select interventions and evaluate outcomes.
Study: NCT05315934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper body aerobic exercise
Description: Participants will perform 30 minutes of continuous exercise on the arm-crank ergometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower body aerobic exercise
Description: Participants will perform 30 minutes of continuous exercise on the cycle ergometer.
Study: NCT02704416

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: catheter ablation of fragmented signal in the right ventricular outflow tract

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Catheter Ablation
Description: catheter ablation of fragmented signal in the right ventricular outflow tract
Study: NCT04564443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medaxis Debritom+
Description: Advanced micro fluid jet therapy to clean and stimulate wound

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sharp Surgical Debridement
Description: Scalpel or Curette to clean and debride wound

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional Outer Dressing Application
Description: Application of moisture retentive dressing, and a multi layer compression dressing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Additional Outer Dressing Application
Description: Application of moisture retentive dressing, and a multi layer compression dressing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offloading
Description: Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Offloading
Description: Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fibracol Wound Dressing
Description: Application of a collagen alginate dressing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fibracol Wound Dressing
Description: Application of a collagen alginate dressing
Study: NCT04464759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Combination of nivolumab, hydroxychloroquine and ipilimumab
Study: NCT01433614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 75 mg/m2 i.v. every 3 weeks, both study arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 75 mg/m2 i.v. every 3 weeks, both study arms
Study: NCT02707965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide (brand name vs generic drugs)
Description: This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
Study: NCT01433614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m2 i.v., every 3 weeks study arm A 155 mg/m2 i.v., every 3 weeks study arm B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m2 i.v., every 3 weeks study arm A 155 mg/m2 i.v., every 3 weeks study arm B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1650 mg/m2 p.o. days 1-14 every 3 weeks study arm B
Study: NCT04495348

Intervention type: DRUG
Intervention: Doravirine
Description: Participants will be switched to doravirine and then switched back to INSTI-based therapy to determine the impact on energy balance.
Study: NCT01201382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPT-AST
Description: A school-based group prevention program that includes 2 individual pre-group sessions, 8 weekly 90 minute group sessions, an individual mid-group session and 4 booster sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Counseling
Description: Usual group counseling as delivered by school counselors; 1 pre-group session, 1 mid-group session, 8 90-minute group sessions, 4 booster sessions
Study: NCT02028065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex 4 mg/kg or 16 mg/kg administered as a single IV bolus over 10 seconds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex 4 mg/kg or 16 mg/kg administered as a single IV bolus over 10 seconds

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as a single IV bolus over 10 seconds
Study: NCT00954070

Intervention type: DEVICE
Intervention: Confocal endomicroscope (Pentax Model EC3870K)
Description: The intervention is an endoscopy procedure using a novel type of endoscope with a powerful confocal microscope attached to its tip. The endoscope (Pentax Model EC3870K) provides both white-light and confocal microscopic imaging.

Intervention type: DEVICE
Intervention: Confocal endomicroscope (Pentax Model EC3870K)
Description: The intervention is an endoscopy procedure using a novel type of endoscope with a powerful confocal microscope attached to its tip. The endoscope (Pentax Model EC3870K) provides both white-light and confocal microscopic imaging.
Study: NCT03358121

Intervention type: DIAGNOSTIC_TEST
Intervention: Clamp study
Description: Clamp study to achieve high, normal, and lower glucose levels to study the dynamics of Asprosin.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clamp study
Description: Clamp study to achieve high, normal, and lower glucose levels to study the dynamics of Asprosin.
Study: NCT04397224

Intervention type: DIAGNOSTIC_TEST
Intervention: Device interrogation
Description: Ventriculo-ventricular conduction time measurement using device analyzer

Intervention type: DIAGNOSTIC_TEST
Intervention: Device interrogation
Description: Ventriculo-ventricular conduction time measurement using device analyzer
Study: NCT03667924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PorchLight Project
Description: Senior Companions (or other LSS-MN volunteers providing senior companionship services) who deliver the PorchLight Project will complete online CARES® Dementia Care Specialist training modules, additional trainings delivered by the research team (1. overview of the PorchLight Project, 2. review of the National Consensus Guidelines on Palliative Care, 3. review of the list of guided questions, and 4. review of journaling approach and LTSS resources), and participate in unstructured monthly check-ins (discussions and case review as applicable) with the research team.
Study: NCT02707965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide (brand name vs generic drugs)
Description: This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin sodium (brand name vs generic drugs)
Description: This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin sodium (brand name vs generic drugs)
Description: This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
Study: NCT00422448

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: To test the frequency of BRAF and NRAS mutations among nevi
Description: Benign nevi excised for the study purpose where genetically analyzed for the presence/absence of BRAF and NRAS mutations
Study: NCT03949504

Intervention type: PROCEDURE
Intervention: New Find-risk questionnaire software
Description: FINDrisk: software with 12 questions to define the risk of diabetes in the general population MyStar Connect: software to guide the diagnosis and the management of diabetes and its complications
Study: NCT00576628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [C.E.R.A.]
Description: Recommended starting dose 1.2 micrograms/kg sc monthly
Study: NCT01173107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine
Description: colchicine 1T tid
Study: NCT03685474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facing Your Fears - School Based
Description: Participants receiving FYF-SB will receive cognitive-behavioral treatment (CBT), which is an evidence-based practice (EBP) for treating anxiety in typical youth, within their school setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants receiving usual care will experience no different therapies, strategies, or recommendations other than what would typically be administered within the school setting in the absence of the proposed study.
Study: NCT04136548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Subjects will receive 75 ug Fentanyl while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
Study: NCT05050968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Between V1 and V2 (i.e. 12 weeks), the APAG (Adapted Physical Activity Group) will participate at a physical training program, 3 sessions of 1h30 per week consisting of endurance activities (60-75% of VO2 peak) and muscle strengthening while the CG will not perform any controlled physical training program. Then, between V2 and V3, no APA (Adapted Physical Activity) program will be offered to both groups.